Brokerages Set Voyager Therapeutics, Inc. (NASDAQ:VYGR) Price Target at $19.33

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have earned an average rating of “Moderate Buy” from the seven research firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $19.33.

A number of brokerages have recently weighed in on VYGR. Guggenheim began coverage on Voyager Therapeutics in a research report on Tuesday, March 26th. They set a “buy” rating and a $22.00 price target on the stock. StockNews.com raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, March 9th. HC Wainwright started coverage on Voyager Therapeutics in a research report on Tuesday, March 19th. They set a “buy” rating and a $30.00 price target for the company. Finally, Citigroup initiated coverage on Voyager Therapeutics in a report on Thursday, March 7th. They set a “buy” rating and a $16.00 price target on the stock.

Voyager Therapeutics Trading Down 2.3 %

Shares of Voyager Therapeutics stock opened at $8.57 on Monday. The business’s 50 day simple moving average is $8.85 and its 200-day simple moving average is $8.03. The stock has a market capitalization of $466.12 million, a price-to-earnings ratio of 2.77 and a beta of 0.98. Voyager Therapeutics has a twelve month low of $6.06 and a twelve month high of $14.34.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Wednesday, February 28th. The company reported $1.25 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $1.84. The business had revenue of $90.06 million for the quarter, compared to analysts’ expectations of $4.95 million. Voyager Therapeutics had a return on equity of 63.89% and a net margin of 52.93%. Sell-side analysts predict that Voyager Therapeutics will post -1.64 earnings per share for the current year.

Institutional Trading of Voyager Therapeutics

Institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp raised its position in Voyager Therapeutics by 0.8% in the third quarter. Bank of New York Mellon Corp now owns 192,869 shares of the company’s stock worth $1,495,000 after acquiring an additional 1,455 shares in the last quarter. Inspire Investing LLC bought a new stake in shares of Voyager Therapeutics in the 3rd quarter worth approximately $641,000. TD Asset Management Inc lifted its stake in Voyager Therapeutics by 100.0% during the third quarter. TD Asset Management Inc now owns 133,502 shares of the company’s stock valued at $1,035,000 after purchasing an additional 66,751 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new stake in Voyager Therapeutics during the third quarter worth approximately $592,000. Finally, Ascension Capital Advisors Inc. acquired a new position in Voyager Therapeutics in the third quarter worth approximately $112,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.